This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The hereditary breast and ovarian cancer syndrome treatment market size has grown strongly in recent years. It will grow from $6.72 billion in 2024 to $7.17 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increased awareness and screening, supportive government policies, patient advocacy and empowerment, collaboration in research.
The hereditary breast and ovarian cancer syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $9.19 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the growing role of artificial intelligence, expanded access to genetic counseling, regulatory approvals for targeted therapies, personalized treatment plans, international collaborations in research. Major trends in the forecast period include gene editing technologies, advancements in immunotherapy, technological advances in oncology, immunotherapy for BRCA-related cancers, comprehensive multidisciplinary care.
The anticipated increase in genetic disorders is set to drive the growth of the hereditary breast and ovarian cancer syndrome treatment market in the coming years. Newborn screening, a post-birth examination for specific health conditions in infants, enables health professionals to identify and address specific needs before any potential health issues arise. This screening could identify infants at a higher risk of developing breast and ovarian cancer, allowing for early preventive measures. In 2022, the Texas Department of State Health Services reported a 4.3% increase in newborn screening specimens received, rising from 729,347 in 2021 to 761,000 in 2022. Of these, approximately 394,000 babies were screened, with 1,130 affected by one of the NBS disorders in 2022. Therefore, the surge in genetic disorders is a key factor propelling the growth of the hereditary breast and ovarian cancer syndrome treatment market.
The rising prevalence of ovarian cancer is expected to further fuel the growth of the hereditary breast and ovarian cancer syndrome treatment market. Ovarian cancer, a malignant tumor in the ovaries, has seen increased prevalence due to factors such as increased longevity, delayed childbearing, and changes in lifestyle. Hereditary Breast and Ovarian Cancer Syndrome (HBOC), a genetic condition elevating the risk of breast, ovarian, and other cancers, is a significant contributor to this trend. According to the World Ovarian Cancer Coalition's February 2022 report, ovarian cancer affected 313,959 women globally in 2020, and this number is projected to rise by 42% to 445,721 between 2020 and 2040. Consequently, the growing prevalence of ovarian cancer is a driving force behind the growth of the hereditary breast and ovarian cancer syndrome treatment market.
Major companies in the hereditary breast and ovarian cancer syndrome treatment market are adopting innovative treatment options, such as comprehensive risk tests, to enhance their services. A comprehensive risk assessment test is a tool designed to identify an individual's risk of developing a disorder or experiencing symptoms of a disease. Genetic Technologies Limited, an Australia-based molecular diagnostics company, launched a groundbreaking comprehensive risk assessment test in February 2023. This test combines gene mutation testing for breast and ovarian cancers, assesses hereditary and non-hereditary risk factors, and calculates the GeneType risk score for both cancers. It targets women over 30 at a higher risk of breast and ovarian cancer in the general population.
In March 2023, Invitae Corporation, a US-based biotechnology company, entered into a partnership with Epic Systems Corporation to streamline the genetic testing process. This collaboration aims to integrate genetic information into standard workflows, facilitating enhanced personalized healthcare delivery within the Epic community. Epic Systems Corporation, a US-based platform provider, plays a crucial role in evaluating a patient's risk for hereditary cancer, including hereditary breast and ovarian cancer syndrome (HBOC).
Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market report are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Vertex Pharmaceuticals Inc., Mercy Health, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Seagen Inc., LEO Pharma Inc., LifeLabs Genetics, Natera Inc., Fresenius Kabi AG, Myriad Genetics Inc., Invitae Corporation, Editas Medicine Inc., GenMark Diagnostics Inc., Genentech Inc., CRISPR Therapeutics AG, Advocate Health Care.
North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary breast and ovarian cancer syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hereditary breast and ovarian cancer syndrome treatment market consists of revenues earned by entities by providing services such as genetic testing and counseling, surveillance, screening, prophylactic surgeries, chemoprevention, clinical trials, ongoing monitoring, family testing, and psychosocial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary breast and ovarian cancer syndrome treatment market also includes sales of lynparza, talazoparib, rucaparib, and niraparib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Treatment for hereditary breast and ovarian cancer syndrome (HBO) refers to a comprehensive set of measures and medical strategies aimed at addressing the heightened risk of developing breast and ovarian cancers in individuals with a genetic predisposition to the syndrome. The objective of hereditary breast and ovarian cancer syndrome (HBO) treatment is to either prevent the onset of cancer or detect it at an early, more treatable stage.
The primary treatments for hereditary breast and ovarian cancer syndrome include hormonal therapy, chemoprevention, genetic counseling, medication, and other therapeutic approaches. Hormone replacement therapy, specifically estrogen-based and of a temporary nature, is targeted at alleviating individual acute symptoms in cases of hereditary breast and ovarian cancer (HBOC) syndrome, particularly in individuals with BRCA1 or BRCA2 mutations. Diagnosis involves genetic testing, magnetic resonance imaging (MRI), mammography, and other methods. Medications can be administered through various routes, including oral, parenteral, and others, with delivery facilitated by hospitals, specialty clinics, home care services, and other healthcare providers.
The hereditary breast and ovarian cancer syndrome market research report is one of a series of new reports that provides hereditary breast and ovarian cancer syndrome market statistics, including hereditary breast and ovarian cancer syndrome industry global market size, regional shares, competitors with a hereditary breast and ovarian cancer syndrome market share, detailed hereditary breast and ovarian cancer syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary breast and ovarian cancer syndrome industry. This hereditary breast and ovarian cancer syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The hereditary breast and ovarian cancer syndrome treatment market size has grown strongly in recent years. It will grow from $6.72 billion in 2024 to $7.17 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increased awareness and screening, supportive government policies, patient advocacy and empowerment, collaboration in research.
The hereditary breast and ovarian cancer syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $9.19 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to the growing role of artificial intelligence, expanded access to genetic counseling, regulatory approvals for targeted therapies, personalized treatment plans, international collaborations in research. Major trends in the forecast period include gene editing technologies, advancements in immunotherapy, technological advances in oncology, immunotherapy for BRCA-related cancers, comprehensive multidisciplinary care.
The anticipated increase in genetic disorders is set to drive the growth of the hereditary breast and ovarian cancer syndrome treatment market in the coming years. Newborn screening, a post-birth examination for specific health conditions in infants, enables health professionals to identify and address specific needs before any potential health issues arise. This screening could identify infants at a higher risk of developing breast and ovarian cancer, allowing for early preventive measures. In 2022, the Texas Department of State Health Services reported a 4.3% increase in newborn screening specimens received, rising from 729,347 in 2021 to 761,000 in 2022. Of these, approximately 394,000 babies were screened, with 1,130 affected by one of the NBS disorders in 2022. Therefore, the surge in genetic disorders is a key factor propelling the growth of the hereditary breast and ovarian cancer syndrome treatment market.
The rising prevalence of ovarian cancer is expected to further fuel the growth of the hereditary breast and ovarian cancer syndrome treatment market. Ovarian cancer, a malignant tumor in the ovaries, has seen increased prevalence due to factors such as increased longevity, delayed childbearing, and changes in lifestyle. Hereditary Breast and Ovarian Cancer Syndrome (HBOC), a genetic condition elevating the risk of breast, ovarian, and other cancers, is a significant contributor to this trend. According to the World Ovarian Cancer Coalition's February 2022 report, ovarian cancer affected 313,959 women globally in 2020, and this number is projected to rise by 42% to 445,721 between 2020 and 2040. Consequently, the growing prevalence of ovarian cancer is a driving force behind the growth of the hereditary breast and ovarian cancer syndrome treatment market.
Major companies in the hereditary breast and ovarian cancer syndrome treatment market are adopting innovative treatment options, such as comprehensive risk tests, to enhance their services. A comprehensive risk assessment test is a tool designed to identify an individual's risk of developing a disorder or experiencing symptoms of a disease. Genetic Technologies Limited, an Australia-based molecular diagnostics company, launched a groundbreaking comprehensive risk assessment test in February 2023. This test combines gene mutation testing for breast and ovarian cancers, assesses hereditary and non-hereditary risk factors, and calculates the GeneType risk score for both cancers. It targets women over 30 at a higher risk of breast and ovarian cancer in the general population.
In March 2023, Invitae Corporation, a US-based biotechnology company, entered into a partnership with Epic Systems Corporation to streamline the genetic testing process. This collaboration aims to integrate genetic information into standard workflows, facilitating enhanced personalized healthcare delivery within the Epic community. Epic Systems Corporation, a US-based platform provider, plays a crucial role in evaluating a patient's risk for hereditary cancer, including hereditary breast and ovarian cancer syndrome (HBOC).
Major companies operating in the hereditary breast and ovarian cancer syndrome treatment market report are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co., AbbVie Inc., Bayer AG, Sanofi-Aventis LLC, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Co. Ltd., Vertex Pharmaceuticals Inc., Mercy Health, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Lupin Limited, Seagen Inc., LEO Pharma Inc., LifeLabs Genetics, Natera Inc., Fresenius Kabi AG, Myriad Genetics Inc., Invitae Corporation, Editas Medicine Inc., GenMark Diagnostics Inc., Genentech Inc., CRISPR Therapeutics AG, Advocate Health Care.
North America was the largest region in the hereditary breast and ovarian cancer syndrome treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary breast and ovarian cancer syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary breast and ovarian cancer syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The hereditary breast and ovarian cancer syndrome treatment market consists of revenues earned by entities by providing services such as genetic testing and counseling, surveillance, screening, prophylactic surgeries, chemoprevention, clinical trials, ongoing monitoring, family testing, and psychosocial support. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary breast and ovarian cancer syndrome treatment market also includes sales of lynparza, talazoparib, rucaparib, and niraparib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Treatment for hereditary breast and ovarian cancer syndrome (HBO) refers to a comprehensive set of measures and medical strategies aimed at addressing the heightened risk of developing breast and ovarian cancers in individuals with a genetic predisposition to the syndrome. The objective of hereditary breast and ovarian cancer syndrome (HBO) treatment is to either prevent the onset of cancer or detect it at an early, more treatable stage.
The primary treatments for hereditary breast and ovarian cancer syndrome include hormonal therapy, chemoprevention, genetic counseling, medication, and other therapeutic approaches. Hormone replacement therapy, specifically estrogen-based and of a temporary nature, is targeted at alleviating individual acute symptoms in cases of hereditary breast and ovarian cancer (HBOC) syndrome, particularly in individuals with BRCA1 or BRCA2 mutations. Diagnosis involves genetic testing, magnetic resonance imaging (MRI), mammography, and other methods. Medications can be administered through various routes, including oral, parenteral, and others, with delivery facilitated by hospitals, specialty clinics, home care services, and other healthcare providers.
The hereditary breast and ovarian cancer syndrome market research report is one of a series of new reports that provides hereditary breast and ovarian cancer syndrome market statistics, including hereditary breast and ovarian cancer syndrome industry global market size, regional shares, competitors with a hereditary breast and ovarian cancer syndrome market share, detailed hereditary breast and ovarian cancer syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary breast and ovarian cancer syndrome industry. This hereditary breast and ovarian cancer syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Characteristics3. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Trends and Strategies4. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Covid and Recovery on the Market32. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market34. Recent Developments in the Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
5. Global Hereditary Breast and Ovarian Cancer Syndrome Treatment Growth Analysis and Strategic Analysis Framework
6. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Segmentation
7. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Regional and Country Analysis
8. Asia-Pacific Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
9. China Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
10. India Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
11. Japan Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
12. Australia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
13. Indonesia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
14. South Korea Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
15. Western Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
16. UK Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
17. Germany Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
18. France Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
19. Italy Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
20. Spain Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
21. Eastern Europe Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
22. Russia Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
23. North America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
24. USA Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
25. Canada Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
26. South America Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
27. Brazil Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
28. Middle East Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
29. Africa Hereditary Breast and Ovarian Cancer Syndrome Treatment Market
30. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Competitive Landscape and Company Profiles
31. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market Other Major and Innovative Companies
35. Hereditary Breast and Ovarian Cancer Syndrome Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on hereditary breast and ovarian cancer syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hereditary breast and ovarian cancer syndrome treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hereditary breast and ovarian cancer syndrome treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment: Hormonal Therapy; Chemoprevention; Genetic Counselling; Medication; Other Treatments2) By Diagnosis: Genetic Testing; Magnetic Resonance Imaging (MRI); Mammography; Other Diagnosis
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors2) By Chemoprevention: Tamoxifen; Raloxifene
3) By Genetic Counselling: Risk Assessment; Family Planning Guidance
4) By Medication: Targeted Therapies; Immune Checkpoint Inhibitors
5) By Other Treatments: Preventive Surgery; Surveillance Strategies
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson Private Limited; F. Hoffmann-La Roche Ltd.; Merck & Co.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Hereditary Breast and Ovarian Cancer Syndrome Treatment market report include:- Pfizer Inc.
- Johnson & Johnson Private Limited
- F. Hoffmann-La Roche Ltd.
- Merck & Co.
- AbbVie Inc.
- Bayer AG
- Sanofi-Aventis LLC
- AstraZeneca plc
- Abbott Laboratories
- GlaxoSmithKline plc
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Daiichi Sankyo Co. Ltd.
- Vertex Pharmaceuticals Inc.
- Mercy Health
- Hikma Pharmaceuticals plc
- Amneal Pharmaceuticals LLC
- Lupin Limited
- Seagen Inc.
- LEO Pharma Inc.
- LifeLabs Genetics
- Natera Inc.
- Fresenius Kabi AG
- Myriad Genetics Inc.
- Invitae Corporation
- Editas Medicine Inc.
- GenMark Diagnostics Inc.
- Genentech Inc.
- CRISPR Therapeutics AG
- Advocate Health Care
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 7.17 Billion |
| Forecasted Market Value ( USD | $ 9.19 Billion |
| Compound Annual Growth Rate | 6.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
